Yahoo
NYSE - Delayed Quote USD

Abbott Laboratories (ABT)

92.71 -1.41 (-1.50%)
At close: June 29 at 4:03:20 PM EDT
93.14 +0.43 (+0.46%)
Pre-Market: 5:05:06 AM EDT
Trade ABT on Coinbase
Dividend
ABT announced a cash dividend of $0.63 with an ex-date of Jul. 15, 2026
Chart Range Bar
Loading chart for ABT

News headlines Abbott Laboratories (ABT) faces challenges as its stock fell 1.5%amid a broader market uptick. Investors are anticipating the July 16 earnings report, which is projected to show EPS of $1.28and revenue growth of 12.43%year-over-year.

Abbott Laboratories (ABT) faces challenges as its stock fell 1.5%amid a broader market uptick. Investors are anticipating the July 16 earnings report, which is projected to show EPS of $1.28and revenue growth of 12.43%year-over-year.

Updated 38m ago · Powered by Yahoo Scout
  • Previous Close 94.12
  • Open 94.54
  • Bid 91.80 x 20000
  • Ask 94.49 x 80000
  • Day's Range 92.67 - 94.97
  • 52 Week Range 81.97 - 137.49
  • Volume 7,724,520
  • Avg. Volume 13,041,725
  • Market Cap (intraday) 161.483B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) 25.97
  • EPS (TTM) 3.57
  • Earnings Date Jul 16, 2026
  • Forward Dividend & Yield 2.52 (2.72%)
  • Ex-Dividend Date Jul 15, 2026
  • 1y Target Est 116.54

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

www.abbott.com

122,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Performance Overview

Trailing total returns as of 6/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABT
25.16%
S&P 500 (^GSPC)
8.69%

1-Year Return

ABT
29.60%
S&P 500 (^GSPC)
20.53%

3-Year Return

ABT
8.55%
S&P 500 (^GSPC)
69.24%

5-Year Return

ABT
13.11%
S&P 500 (^GSPC)
73.36%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 11.16B
Earnings 2.02B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
2B
4B
6B
8B
10B

Analyst Insights

View More

Analyst Price Targets

92.00
116.54 Average
92.71 Current
135.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/22/2026
Analyst Piper Sandler
Rating Action Reiterates
Rating Overweight
Price Action Maintains
Price Target 115 -> 115

Statistics

View More

Valuation Measures

Annual
As of 6/29/2026
  • Market Cap

    161.48B

  • Enterprise Value

    188.24B

  • Trailing P/E

    25.97

  • Forward P/E

    16.92

  • PEG Ratio (5yr expected)

    1.38

  • Price/Sales (ttm)

    3.59

  • Price/Book (mrq)

    3.10

  • Enterprise Value/Revenue

    4.17

  • Enterprise Value/EBITDA

    15.90

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.90%

  • Return on Assets (ttm)

    5.59%

  • Return on Equity (ttm)

    12.33%

  • Revenue (ttm)

    45.13B

  • Net Income Avi to Common (ttm)

    6.25B

  • Diluted EPS (ttm)

    3.57

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.3B

  • Total Debt/Equity (mrq)

    64.77%

  • Levered Free Cash Flow (ttm)

    6.34B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

92.71 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 06/22/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • US Large Cap Pick List - May 2026

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

  • US Large Cap Pick List - June 2026

    This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither growth nor value characteristics predominate. Stocks in the top 70% of the capitalization of the U.S. equity market are defined as large cap.

  • Daily – Vickers Top Buyers & Sellers for 04/29/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: